儿童和青少年患有严重喘和中度至严重的亚托皮炎的药物相关感知:一项非干预性探索性研究
Markus Herzig1, Maike Vom Hove2,3, Astrid Bertsche3,4,5
1Clinical Pharmacy, Institute of Pharmacy, Medical Faculty, Leipzig University and Drug Safety Center, Leipzig University and University Hospital, Bruederstrasse 32, D-04103, Leipzig, Germany.
患有严重喘和亚托邦性皮肤炎的儿科患者发现他们的治疗方法有帮助. 在儿童和青少年中,杜皮卢马布治疗显示出显著的疾病改善和减少注射恐惧.
科学领域:
- 儿科皮肤学 儿科皮肤学
- 儿科肺病学 儿科肺病学
- 临床免疫学 临床免疫学
背景情况:
- 严重的喘和中度至严重的亚托邦皮肤炎显著影响儿科患者的生活质量.
- 有限的现实世界数据存在于儿科患者对治疗这些疾病的药物的看法.
研究的目的:
- 探索儿科患者对他们治疗严重喘和/或中度至严重的亚托皮炎的药物的看法.
- 评估在这个人群中使用dupilumab治疗的现实有效性和患者经验.
主要方法:
- 一项非干预性,横截面研究,涉及57名患有严重喘和/或中度至严重的亚托皮性皮肤炎的儿科患者 (6-17岁).
- 采用开放式问题和6分利克特尺度进行了结构化采访.
- 接受dupilumab治疗的患者需要至少16周的治疗时间.
主要成果:
- 患者报告了"相当温和"的喘和皮炎负担,认为他们的药物"相当有帮助".
- 虽然21%的人最初因为不情愿而拒绝服用药物,但所有人都恢复了治疗.
- 所有接受杜皮卢马布治疗的16名参与者在2.5个月内报告了疾病的改善,注射恐惧显著减少.
结论:
- 儿科患者认为当前的治疗方法对治疗喘和亚托邦性皮肤炎非常有益.
- 杜皮卢马布治疗耐受性良好,有效改善儿科患者的疾病症状和减少与治疗有关的焦虑.
更多相关视频
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
06:31Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-I: Introduction
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Inhaled Medications
